Medpace Holdings Inc (NASDAQ:MEDP) – SunTrust Banks upped their Q3 2019 EPS estimates for shares of Medpace in a research note issued to investors on Tuesday, July 30th, Zacks Investment Research reports. SunTrust Banks analyst S. Draper now expects that the company will post earnings per share of $0.73 for the quarter, up from their previous estimate of $0.67. SunTrust Banks currently has a “Buy” rating and a $85.00 price target on the stock. SunTrust Banks also issued estimates for Medpace’s Q4 2019 earnings at $0.71 EPS.
A number of other equities research analysts have also recently commented on the stock. Credit Suisse Group raised their target price on shares of Medpace from $65.00 to $77.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 30th. TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a research note on Thursday, June 6th. Robert W. Baird lifted their price objective on shares of Medpace from $57.00 to $62.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 30th. Zacks Investment Research raised shares of Medpace from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research note on Wednesday, July 10th. Finally, BidaskClub raised shares of Medpace from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $73.75.
NASDAQ MEDP traded down $1.03 on Thursday, reaching $78.91. 240,665 shares of the stock were exchanged, compared to its average volume of 529,126. Medpace has a one year low of $45.88 and a one year high of $82.39. The firm has a market capitalization of $2.87 billion, a PE ratio of 30.47, a PEG ratio of 2.22 and a beta of 1.57. The company’s 50-day simple moving average is $70.97 and its two-hundred day simple moving average is $61.82. The company has a current ratio of 0.66, a quick ratio of 0.66 and a debt-to-equity ratio of 0.07.
Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, July 29th. The company reported $0.81 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.18. Medpace had a net margin of 11.28% and a return on equity of 17.65%. The firm had revenue of $214.10 million for the quarter, compared to analysts’ expectations of $200.99 million. During the same quarter in the prior year, the business earned $0.61 EPS. The business’s quarterly revenue was up 25.8% on a year-over-year basis.
A number of hedge funds and other institutional investors have recently bought and sold shares of MEDP. Pearl River Capital LLC purchased a new position in Medpace during the second quarter worth $27,000. FTB Advisors Inc. lifted its position in shares of Medpace by 171.8% during the second quarter. FTB Advisors Inc. now owns 579 shares of the company’s stock worth $37,000 after purchasing an additional 366 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Medpace by 53.9% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 605 shares of the company’s stock worth $40,000 after purchasing an additional 212 shares during the last quarter. Advisor Group Inc. lifted its position in shares of Medpace by 18.7% during the second quarter. Advisor Group Inc. now owns 1,462 shares of the company’s stock worth $95,000 after purchasing an additional 230 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Medpace during the first quarter worth $99,000. 81.44% of the stock is owned by institutional investors.
About Medpace
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.